Basilea Receives Request to Place Repayment of CHF 48 Million From Capital Contribution Reserve on the Agenda of the Ordinary

Basilea Receives Request to Place Repayment of CHF 48 Million From Capital 
Contribution Reserve on the Agenda of the Ordinary General
Meeting of Shareholders 
BASEL, SWITZERLAND -- (Marketwire) -- 02/22/13 --  Basilea
Pharmaceutica Ltd. (SIX: BSLN) has received a request from one of its
shareholders, HBM Healthcare Investments (Cayman) Ltd., which holds
more than 20% of Basilea's shares, to place the repayment of CHF 5.00
per registered share from the company's capital contribution reserve
on the agenda of Basilea's upcoming ordinary general meeting of
shareholders, for a total of approximately CHF 48 million. 
Basilea's board of directors will carefully evaluate the request. 
Basilea's ordinary general meeting of shareholders is scheduled for
April 9, 2013. The deadline for registration in the share register to
vote at the ordinary general meeting of shareholders is March 28,
2013. 
About Basilea 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland,
and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully
integrated research and development operations of its Swiss subsidiary
Basilea Pharmaceutica International Ltd., the company focuses on
innovative pharmaceutical products in the therapeutic areas of
bacterial infections, fungal infections and oncology, targeting the
medical challenge of rising resistance and non-response to current
treatment options. 
Disclaimer 
This communication expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Basilea
Pharmaceutica Ltd. to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing
this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise. 
This press release can be downloaded from www.basilea.com. 
Press release (PDF): 
http://hugin.info/134390/R/1680620/549123.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein. 
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE 
[HUG#1680620] 
For further information, please contact: 
Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com 
Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
investor_relations@basilea.com